Advertisement

Treatment Effect in Benign and Malignant Prostate Tissue

  • Rajal B. ShahEmail author
  • Ming Zhou
Chapter

Abstract

Prostate lesions are managed by surgical and nonsurgical modalities, including observation, active surveillance, surgical resection, ablation by physical methods such as cryoablation and thermal ablation, and drugs that target the androgen pathways. Treatment may cause significant changes in morphology of both benign and malignant prostate tissues. Such changes may pose a significant challenge in diagnosis and grading of prostate cancer, particularly in needle biopsy specimens. In addition, prostate cancer with treatment effect should not be Gleason-graded as therapy-induced architectural changes, upon which Gleason grading is based, are not indicative of its biological behavior. Treatment history is, however, not always provided by clinicians. Therefore, pathologists should be aware of the histological changes associated with treatments in benign and malignant prostate tissue.

Keywords

Treatment effect Radiation Total androgen blockade First-generation antiandrogen Second-generation antiandrogen Aromatase inhibitor Laser ablation Cryoablation Benign prostate tissue Malignant prostate tissue Treatment modalities for prostate lesions Histological changes Androgen deprivation Mucin lake Foamy histiocytes Cryotherapy Hyperthermia Grading radiation effect 

References

  1. 1.
    Evans AJ. Treatment effects in prostate cancer. Mod Pathol. 2018;3:S110–21.CrossRefGoogle Scholar
  2. 2.
    NCCN Clinical Practice Guideline in Oncology: Prostate Cancer. 2018. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Last accessed 16 Sept 2018.
  3. 3.
    Banerjee PP, Banerjee S, Brown TR, Zirkin BR. Androgen action in prostate function and disease. Am J Clin Exp Urol. 2018;6:62–77.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Tetu B. Morphological changes induced by androgen blockade in normal prostate and prostatic carcinoma. Best Pract Res Clin Endocrinol Metab. 2008;22:271–83.CrossRefGoogle Scholar
  5. 5.
    Gleave M, Qian J, Andreou C, Pommerville P, Chin J, Casey R, et al. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer – results from a 4-month pre-radical prostatectomy study. Prostate. 2006;66:1674–85.CrossRefGoogle Scholar
  6. 6.
    Yang XJ, Lecksell K, Short K. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology. 1999;53:696–700.CrossRefGoogle Scholar
  7. 7.
    Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99:1375–83.CrossRefGoogle Scholar
  8. 8.
    Crook JM, Malone S, Perry G, Eapen L, Owen J, Robertson S, et al. Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: results from a Canadian randomized trial. Cancer. 2009;115:673–9.CrossRefGoogle Scholar
  9. 9.
    Magi-Galluzzi C, Sanderson H, Epstein JI. Atypia in nonneoplastic prostate glands after radiotherapy for prostate cancer: duration of atypia and relation to type of radiotherapy. Am J Surg Pathol. 2003;27:206–12.CrossRefGoogle Scholar
  10. 10.
    Borkowski P, Robinson MJ, Poppiti RJ Jr, Nash SC. Histologic findings in postcryosurgical prostatic biopsies. Mod Pathol. 1996;9:807–11.PubMedGoogle Scholar
  11. 11.
    Biermann K, Montironi R, Lopez-Beltran A, Zhang S, Cheng L. Histopathological findings after treatment of prostate cancer using high-intensity focused ultrasound (HIFU). Prostate. 2010;70:1196–200.CrossRefGoogle Scholar
  12. 12.
    Van Leenders GJ, Beerlage HP, Ruijter ET, de la Rosette JJ, van de Kaa CA. Histopathological changes associated with high intensity focused ultrasound (HIFU) treatment for localised adenocarcinoma of the prostate. J Clin Pathol. 2000;53:391–4.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Robert J Tomsich Pathology and Laboratory Medicine InstituteCleveland ClinicClevelandUSA
  2. 2.Tufts Medical CenterBostonUSA

Personalised recommendations